```html

Xerophthalmic Conjunctivitis

Overview

Xerophthalmic conjunctivitis (also called dry‑eye conjunctivitis or evaporative conjunctivitis) is an inflammatory condition of the conjunctiva that occurs secondary to chronic dryness of the ocular surface. When the tear film is insufficient or of poor quality, the delicate lining of the eye becomes irritated, leading to redness, itching, and a gritty sensation.

It most commonly affects adults over the age of 40, but younger individuals can develop it when they have underlying risk factors such as prolonged screen time, certain medications, or autoimmune disease.

• Prevalence: Dry‑eye disease (DED) – the broader condition that includes xerophthalmic conjunctivitis – affects an estimated 5‑30 % of the global population, with prevalence rising to >30 % in people older than 50 years (source: NIH, 2020).
• Women are approximately 2‑3 times more likely to develop DED, reflecting hormonal influences.
• In the United States, more than 16 million adults report symptoms consistent with dry‑eye disease (CDC, 2022).

Symptoms

Because xerophthalmic conjunctivitis is a manifestation of tear‑film deficiency, its symptoms often overlap with those of dry‑eye disease. The full range includes:

• Redness (hyperemia): Dilated conjunctival vessels give the eye a pink or blood‑shot appearance.
• Grittiness or foreign‑body sensation: Patients frequently describe feeling as if “sand” is in the eye.
• Burning or stinging: May be intermittent or constant, worsening in dry environments.
• Itching: Often mild, but can become more pronounced if secondary allergic inflammation occurs.
• Excessive tearing (reflex lacrimation): Paradoxically, the eye may produce watery discharge as a reflex to irritation.
• Blurred vision: Typically improves with blinking; may become persistent if the cornea is affected.
• Eye fatigue: A feeling of heaviness after prolonged visual tasks (e.g., reading, screen use).
• Mucous or stringy discharge: Not purulent; usually clear or slightly mucoid.
• Sensitivity to light (photophobia): Mild in most cases, more marked if there is associated corneal epithelial breakdown.
• Contact lens intolerance: Discomfort that leads patients to remove lenses more often.

Causes and Risk Factors

Pathophysiology

Normal tear film comprises three layers (lipid, aqueous, mucus). Disruption of any layer can increase tear evaporation or reduce tear volume, leading to ocular surface inflammation. The resulting cytokine cascade (e.g., IL‑1, TNF‑α) triggers conjunctival hyperemia and the clinical picture of xerophthalmic conjunctivitis.

Primary Causes

• Meibomian gland dysfunction (MGD): The most common cause of evaporative dry eye; altered lipid secretion accelerates tear evaporation.
• Aqueous‑deficient dry eye: Reduced tear production from lacrimal gland hypofunction (e.g., Sjögren’s syndrome, aging).
• Environmental factors: Low humidity, wind, air‑conditioned or heated rooms, smoke, and prolonged screen exposure.
• Medication‑induced dryness: Antihistamines, antidepressants, β‑blockers, isotretinoin, and diuretics.
• Ocular surface surgery or laser procedures that disrupt corneal nerves and tear reflexes.

Risk Factors

• Age > 40 years
• Female sex (especially post‑menopausal)
• Autoimmune disorders (Sjögren’s, rheumatoid arthritis, lupus)
• History of ocular surgery (LASIK, cataract extraction)
• Contact lens wear, especially extended‑wear lenses
• Occupations with high screen time or exposure to wind/air‑conditioning (e.g., office work, pilots)
• Systemic diseases that affect nerves (diabetes, Parkinson’s disease)
• Use of systemic or topical medications that reduce tear production

Diagnosis

Diagnosis is clinical, supported by specific bedside tests and occasionally laboratory work‑up to rule out underlying systemic disease.

History & Physical Examination

• Detailed symptom inventory (onset, duration, aggravating/relieving factors).
• Medication review and environmental exposure assessment.
• External ocular examination with slit‑lamp microscopy to evaluate conjunctival injection, tear‑film break‑up time (TBUT), and corneal staining.

Common Diagnostic Tests

• Schirmer I test: Filter paper strips placed under the lower eyelid for 5 minutes; ≤ 5 mm wetting suggests aqueous deficiency.
• Tear‑film breakup time (TBUT): Fluorescein dye is applied; a TBUT < 10 seconds is abnormal, indicating tear instability.
• Ocular surface staining: Fluorescein, lissamine green, or rose bengal highlight damaged epithelial cells.
• Meibography: Infrared imaging of meibomian glands to assess dropout or obstruction.
• Osmolarity testing: Elevated tear osmolarity (> 308 mOsm/L) is a diagnostic marker for dry‑eye disease.
• Inflammatory markers: Point‑of‑care tests (e.g., MMP‑9) can quantify ocular surface inflammation.
• Serologic work‑up: ANA, SSA/SSB antibodies if autoimmune disease is suspected.

Differential Diagnosis

Conditions that may mimic xerophthalmic conjunctivitis include allergic conjunctivitis, bacterial/viral conjunctivitis, blepharitis, and ocular surface pemphigoid. A thorough exam helps differentiate them.

Treatment Options

Management follows a step‑ladder approach: start with conservative measures, advance to pharmacologic therapy, and consider procedural interventions when needed.

1. Lifestyle and Environmental Modifications

• Increase ambient humidity (humidifiers, especially during winter).
• Take regular screen breaks (20‑20‑20 rule: every 20 minutes look at something 20 feet away for 20 seconds).
• Avoid direct air flow from fans or AC vents.
• Wear protective sunglasses outdoors to reduce evaporation.
• Stay hydrated – at least 2 L of water per day.

2. Artificial Tears & Tear Substitutes

• Preservative‑free lubricants: 1–2 drops every hour as needed; preferred for chronic use.
• Gel or ointment formulations: Apply at night for prolonged ocular surface coverage.
• Examples: Refresh Optive, Systane Ultra, or generic hyaluronic‑acid drops (evidence grade A, Mayo Clinic).

3. Anti‑Inflammatory Therapy

• Topical cyclosporine A 0.05 % (Restasis) or 0.1 % (Cequa): Improves tear production and reduces inflammation; benefits often seen after 3–6 months.
• Lifitegrast 5 % (Xiidra): An integrin antagonist that alleviates ocular surface inflammation.
• Short‑course corticosteroid eye drops: Prednisolone acetate 1 % used for 1–2 weeks during acute flare‑ups, under physician supervision.

4. Meibomian Gland Therapy

• Warm compresses: 5–10 minutes, 2–3 times daily to melt obstructed meibum.
• Lid hygiene: Gentle massage followed by cleansing with diluted baby shampoo or commercial lid scrubs.
• Thermal pulsation devices (e.g., LipiFlow®): In‑office procedure that applies controlled heat and massage; meta‑analysis shows 30‑40 % improvement in symptom scores (Cleveland Clinic, 2021).
• Meibomian gland expression: Manual or instrument‑assisted clearing of clogged glands.

5. Punctal Occlusion

Placement of temporary (collagen) or permanent (silicone) plugs in the lower puncta reduces tear drainage, increasing ocular surface moisture. Indicated when topical therapy alone is insufficient.

6. Systemic Therapy (Select Cases)

• Omega‑3 fatty acid supplements (1000 mg EPA/DHA) have modest benefit for MGD.
• For autoimmune dryness (e.g., Sjögren’s), systemic agents such as hydroxychloroquine may be prescribed by a rheumatologist.

7. Emerging Treatments

• Autologous serum eye drops: Contain growth factors and vitamins; used for severe refractory cases.
• Topical recombinant lubricin: Under clinical investigation; early trials show reduced friction and inflammation.

Living with Xerophthalmic Conjunctivitis

Chronic eye conditions can affect daily life, but practical habits can markedly improve comfort.

Daily Management Tips

• Establish a drop schedule: Keep a log or set phone reminders to ensure consistent use of lubricants and anti‑inflammatories.
• Carry a small travel‑size bottle of preservative‑free drops for use at work or on the go.
• Apply a warm compress in the evening; follow with lid massage and a night‑time ointment.
• Use a humidifier while sleeping, especially in dry climates.
• Wear wrap‑around sunglasses to protect against wind and UV light.
• Limit caffeine and alcohol, which can exacerbate dehydration.
• Schedule regular eye‑care follow‑up (every 6–12 months) to monitor disease progression.

Work & Study Adjustments

• Adjust computer monitor height to reduce palpebral fissure exposure.
• Use anti‑glare screen filters.
• Take “blink breaks” every 15 minutes – consciously close eyes for a few seconds.
• Consider using artificial tear reminders integrated into computer software.

Contact Lens Considerations

If you wear contacts, discuss options with your eye‑care professional. Daily disposable lenses or silicone‑hydrogel lenses with high oxygen permeability are preferred. Some patients may need to pause lens wear during flare‑ups.

Prevention

While some risk factors (age, genetics) cannot be changed, many preventive measures are within reach:

• Maintain optimal hydration and a balanced diet rich in omega‑3 fatty acids (e.g., fish, flaxseed).
• Control systemic diseases such as diabetes and rheumatoid arthritis.
• Limit exposure to smoke, wind, and harsh chemicals.
• Avoid over‑use of over‑the‑counter decongestant eye drops, which can worsen dryness.
• Have yearly comprehensive eye exams, especially after age 40.
• Use preservative‑free artificial tears prophylactically if you work in dry or air‑conditioned environments.

Complications

If left untreated, persistent ocular surface inflammation can lead to:

• Corneal epithelial breakdown: Persistent dryness may cause micro‑abrasions, increasing infection risk.
• Superficial punctate keratitis: Small, diffuse lesions that cause pain and visual fluctuation.
• Conjunctival scarring (fibrosis): Rare but can affect eyelid function.
• Increased susceptibility to bacterial or viral conjunctivitis.
• Reduced quality of life: Chronic discomfort can affect sleep, work productivity, and mental health.

When to Seek Emergency Care

---

References:

• National Eye Institute (NEI). “Dry Eye Disease.” NIH, 2020. https://www.nei.nih.gov
• Mayo Clinic. “Dry eye.” Updated 2023. https://www.mayoclinic.org
• Cleveland Clinic. “Meibomian Gland Dysfunction.” 2021. https://my.clevelandclinic.org
• American Academy of Ophthalmology. “Dry Eye.” 2022. https://www.aao.org
• World Health Organization. “Prevalence of ocular surface disease.” WHO Global Report, 2021.
• U.S. Centers for Disease Control and Prevention. “Vision Health Initiative.” 2022.

```